We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Clinigen Group Plc | CLIN | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 925.00 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 925.00 |
| Top Posts |
|---|
Posted at 27/12/2021 12:25 by paying4it At this time of year is there enough time for individual investors to receive a corporate action from their respective trading platforms decide whether to accept or decline the offer and reply and the platforms to correlate this and pass it on to whoever deals with the numbers I a share holder in the company have not received any communication yet I am guessing any of the professionals dealing with this will be on their holidays at the moment as well I am at the moment planning on rejecting the offer although that will be reconsidered as things pan Out anybody else know what they are considering Hope your all enjoying the festive break |
Posted at 24/11/2021 18:33 by value viper No trading update but clear dissent with institutional investors re pay and director roles - not surprising frankly. The share price performance is dire for what they get paid etc - all aligned with Elliott's now involvement - change is needed |
Posted at 29/6/2021 04:24 by brummy_git Just in case you missed it yesterday.Marvellous insights from Christopher Mills of Harwood Capital - a world class investor - talking about top quality stocks, such as Clinigen. Heaven personified www.linkedin.com/pos |
Posted at 09/6/2021 10:36 by pennypincher5 IMHO proleukin is a huge risk and has saddled company with a level of debt it seems unable to shift. Time will tell if this pays off. It’s largely out of Clinigen’s hands given it relies on 3rd parties to find new indications (such as Iovance). Investors should look to past performance on other products and the service side of business as well as proleukin - however changes in reporting year on year make this difficult. |
Posted at 09/6/2021 09:50 by hjs Imo- the share price drop today is just a blip. I am already invested. It is a very good opportunity to add some more or new investors to buy this stock.Value V- you may be right, private equity may run a slide rule now and grab a bargain. This is covid impacted stock and will recover as soon as we open up. |
Posted at 02/12/2020 19:41 by ali47fish was'nt a dividend due today- or was it suspended/delayed? i think it was on the investor chronicle calendar for this week |
Posted at 23/6/2020 15:55 by adamb1978 ok, it's just media speculation...and a HIGHLY misleading message from YouInvest!!There's an article on practive investors hxxps:// www.proactiveinvesto companies/news/92189 clinigen-circled-by- |
Posted at 19/9/2019 12:20 by cfro FD share purchase..market reacting well to the results now. the decline of Foscavir sales are well known now and should more or less be factored in. Investors will likely now be looking beyond that. Agree there are lots of adjusted numbers but it is best to look through these at the underlying business and business model. |
Posted at 21/1/2019 09:19 by aim_trader Clinigen will be presenting to investors at the Proactive One2One Investor Forum taking place on the evening of Thursday 24th January 2019. For details and registration here: |
Posted at 04/11/2018 14:30 by maxdave Tipped in Sunday Times today (Inside the City).".... Stifel has an £11 target on the stock, while stockbroker Peel Hunt has valued the shares at £13.50. Maybe wannabe investors should take note. Buy" |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
